Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (468)	7/22/1999 10:49:00 PM
From: squetch	Read Replies (1) \| Respond to of 717

Some Phase III Gd-Tex questions. Any guesses as to when the 2/3 look will take place? >>the median survival of patients with brain metastases treated with radiation therapy is approximately 3-4 months...The FDA has agreed that the proposed Phase III trial qualifies for "fast track" review, should efficacy end points be met. A single pivotal trial is adequate for approval, since survival, rather than a surrogate end point, is the primary end point of the study.<< What are those efficacy end points going to be? That maybe a stupid question, but it took me 10 months to think of it.(:>)